New trends in antiretroviral therapy for HIV infection (Q73289988)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113653 AND SRC:MED&resulttype=core&format=json

2 November 2019

title

New trends in antiretroviral therapy for HIV infection (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113653 AND SRC:MED&resulttype=core&format=json

2 November 2019

author name string

Joly V V

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113653 AND SRC:MED&resulttype=core&format=json

2 November 2019

Yeni P

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113653 AND SRC:MED&resulttype=core&format=json

2 November 2019

publication date

1 December 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113653 AND SRC:MED&resulttype=core&format=json

European Journal of Internal Medicine

2 November 2019

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113653 AND SRC:MED&resulttype=core&format=json

2 November 2019

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113653 AND SRC:MED&resulttype=core&format=json

2 November 2019

issue

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113653 AND SRC:MED&resulttype=core&format=json

2 November 2019

page(s)

301-308

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113653 AND SRC:MED&resulttype=core&format=json

A randomized trial of three maintenance regimens given after three months of induction therapy with zidovudine, lamivudine, and indinavir in previously untreated HIV-1-infected patients. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study

2 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Maintenance therapy after quadruple induction therapy in HIV-1 infected individuals: Amsterdam Duration of Antiretroviral Medication (ADAM) study

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Maintenance antiretroviral therapies in HIV-infected subjects with undetectable plasma HIV RNA after triple-drug therapy. AIDS Clinical Trials Group Study 343 Team

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Mechanisms of virologic failure in previously untreated HIV-infected patients from a trial of induction-maintenance therapy. Trilège (Agence Nationale de Recherches sur le SIDA 072) Study Team).

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Drug susceptibility in HIV infection after viral rebound in patients receiving indinavir-containing regimens

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Factors influencing the emergence of resistance to indinavir: role of virologic, immunologic, and pharmacologic variables.

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Drug-resistance genotyping in HIV-1 therapy: the VIRADAPT randomised controlled trial.

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

The effect of treatment intensification in HIV-infection: a study comparing treatment with ritonavir/saquinavir and ritonavir/saquinavir/stavudine. Prometheus Study Group

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Emergence of zidovudine and multidrug-resistance mutations in the HIV-1 reverse transcriptase gene in therapy-naive patients receiving stavudine plus didanosine combination therapy. STADI Group

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

HIV-1 genotypic resistance patterns predict response to saquinavir-ritonavir therapy in patients in whom previous protease inhibitor therapy had failed

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Novel four-drug salvage treatment regimens after failure of a human immunodeficiency virus type 1 protease inhibitor-containing regimen: antiviral activity and correlation of baseline phenotypic drug susceptibility with virologic outcome

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

A syndrome of peripheral lipodystrophy, hyperlipidaemia and insulin resistance in patients receiving HIV protease inhibitors

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Visceral abdominal-fat accumulation associated with use of indinavir

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

“Buffalo hump” in men with HIV-1 infection

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

A syndrome of peripheral fat wasting (lipodystrophy) in patients receiving long-term nucleoside analogue therapy

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Accelerated bone mineral loss in HIV-infected patients receiving potent antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Positive effects of combined antiretroviral therapy on CD4 T cell homeostasis and function in advanced HIV disease

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Overshoot of HIV-1 viraemia after early discontinuation of antiretroviral treatment

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Control of HIV despite the Discontinuation of Antiretroviral Therapy

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

Structured treatment interruption in chronically HIV-1 infected patients after long-term viral suppression

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

HIV-1 rebound during interruption of highly active antiretroviral therapy has no deleterious effect on reinitiated treatment. Comet Study Group

1 reference

https://api.crossref.org/works/10.1016/S0953-6205(00)00112-6

7 January 2021

10.1016/S0953-6205(00)00112-6

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:11113653 AND SRC:MED&resulttype=core&format=json

2 November 2019

1 reference